Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Go back to Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 528.90 -17.22 (3.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $546.12 | 52 Week High | $134.71 | |||
| Open | $529.64 | 52 Week Low | $73.31 | |||
| Day High | $535.00 | P/E | N/A | |||
| Day Low | $520.20 | EPS | $-1.98 | |||
| Volume | 1,121,341 | |||||
